used an anti-HER-2 antibody to modify photosensitizer C11Pc to prepare novel nanomedicines (Anti-HER2-C11Pc-PEG-AuNPs) for PDT combination therapy of breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.